Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
TC BioPharm Ltd
TCBP
Healthcare
Biotechnology
TC BioPharm Limited is a clinical-stage biopharmaceutical company. The Company is engaged in developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma-delta T cell therapies for the treatment of infectious disease. The Company's platform technology allows the Company to design specific therapies to treat a range of cancers and infectious...
diseases with off-the-shelf allogeneic gamma-delta T cell (GDT) products. The Company’s pipeline includes OmnImmune and CAR-T programs. OmnImmune is an unmodified allogeneic gamma-delta T cell product being used for the treatment of acute myeloid leukemia (AML). The Company has completed a Phase II clinical trial. Its CAR-T programs include in-house and partner programs at the pre-clinical-stage focused on developing CAR modified allogeneic gamma delta T-cell products targeting solid and hematological indications.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:TCBP)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
Next
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Feb 09, 2024 9:06am
TCBP...early a.m runner on No News
big volume on this "thinner"....$1.59 On watch need more DD
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Mar 07, 2023 8:30am
New Press Release - TC BioPharm Shifts Focus to FDA Clinical Trials
Company to explore US IND pathway for additional combination trialsEDINBURGH, Scotland, March 7, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for...
read article.
Xcyte Digital Corp. Releases "Xperience" Subscription Service
posted May 17, 2024 9:00am by
Xcyte Digital Corp.
-
|
"Xcyte anticipates growing the Xperience one-stop offering further with additional event technologies and supporting services, such as digital marketing and lead generation. We look forward to providing future updates as we execute upon this growth strategy ...read more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Feb 23, 2023 8:30am
New Press Release - TC BioPharm Announces Dr. Mike Leek as Chief Technology Officer
EDINBURGH, Scotland, Feb. 23, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the appointment of Dr. Michael Leek to the...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Feb 21, 2023 8:30am
New Press Release - TC BioPharm Announces Publication of Paper in AML Research Highlighting the Company's Development of Allogeneic Gamma-Delta T cell Therapies
EDINBURGH, Scotland, Feb. 21, 2023 /PRNewswire/ -- TC BioPharm(Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced today the publication of a paper...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Feb 14, 2023 8:30am
New Press Release - TC BioPharm Announces New Chair of the Board, Arlene Morris
EDINBURGH, Scotland, Feb. 14, 2023 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the appointment of Arlene M...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Feb 13, 2023 4:15pm
New Press Release - TC BioPharm to Reschedule Shareholder Update Call and Webcast
Conference Call to be held on Tuesday, February 21st, 2023 at Noon ETEDINBURGH, Scotland, Feb. 13, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Feb 07, 2023 8:30am
New Press Release - TC BioPharm Announces Successful Dosing of Final Patient in ACHIEVE Safety Cohort
Phase 2B Clinical Trial Evaluating Omnimmune® in AML PatientsEDINBURGH, Scotland, Feb. 7, 2023 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell...
read article.
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 30, 2023 11:23am
TCBP......Love being right
Especially against the "majority" Sub $5 now Wait for it ; )
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 30, 2023 11:04am
TCBP.... Come on....just cut to the chase ; )
Drop like u know u can !
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 30, 2023 10:17am
TCBP.... I could have sworn that I read this was....
going to $9..... WTF? Told u it was BS ; )
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 30, 2023 10:03am
TCBP ..... Last week it gets pumped for the dump
LoL
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jan 30, 2023 8:30am
New Press Release - TC BioPharm Announces Hiring of Chief Clinical Officer Bree Harlin to Lead Global Clinical Division
Will oversee expansion of U.S. FDA Clinical TrialsEDINBURGH, Scotland, Jan. 30, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for...
read article.
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Comment by
Iseneschal
on Jan 27, 2023 2:24pm
RE:TCBP...Latest news (ystrdy) was an upgrade & $9 price target
This is definetly worth a repeat ; ) I saved ur a$$e$ again !!!!
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 27, 2023 8:37am
TCBP...Latest news (ystrdy) was an upgrade & $9 price target
Started it's run yesterday and is still continueing this a.m I'll stick with what I know and say this is being set up for a financing It's now traded about 10 million shares since the RS
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jan 20, 2023 8:30am
New Press Release - TC BioPharm to Host Shareholder Update Call
Conference Call to be held on Monday, February 20th, 2023 at 10:00 am ETEDINBURGH, Scotland, Jan. 20, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta...
read article.
Prev
1
2
3
4
5
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Drilling Approval Received for New Mexico Lithium Project
GameSquare Announces Formation of FaZe Media, Backed by $11M Investment
Xcyte Digital Corp. Releases "Xperience" Subscription Service